Category: Pharma News
-
PACE adds £6 million in funding to combat superbugs
The funding is part of a broader £30 million investment from PACE, one of the UK’s largest public-private initiatives, to accelerate solutions for global AMR challenges.
-
ERS 2025: Boehringer shares additional data for lung fibrosis therapy
Pooled Phase III data show nerandomilast may reduce death risk in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
-
Osaka’s gambit: Transforming Japan’s pharma sector
Japan is showcasing its new ecosystem where academia, industry, and government converge to deliver not just world-class science but also leadership in medicine.
-
Aphaia Pharma publishes Phase I and II data for obesity therapy
Aphaia’s coated glucose microbeads show promise in improving glucose tolerance and metabolic health with a favorable safety profile.
-
Chiesi scores FDA priority review for rare vision disorder
Raxone is approved for Leber Hereditary Optic Neuropathy (LHON), a rapid vision-loss disease, in multiple countries, including the EU.
-
EADV 2025: Affibody’s izokibep shows strong Phase III results in HS
Phase III trial data presented at EADV 2025 highlight a 75% reduction in abscesses and inflammatory nodules with izokibep in hidradenitis suppurativa (HS).
-
EASD 2025: Amgen highlights real-world challenges in obesity management
Amgen spotlights real-world GLP-1 adherence challenges and advances MariTide in the evolving obesity treatment landscape.
-
Lipella reports positive Phase IIa results for LP-10 in oral lichen planus
The Phase IIa trial met its primary safety endpoint and achieved statistically significant improvements across all efficacy measures at the four-week mark.
-
EASD 2025: MitoRx reports preclinical data on muscle preservation in obesity
MitoRx’s Myo4 showed preserved muscle mass and reduced liver fat in a diet-induced obesity mouse model.
-
ECTRIMS 2025: Sanofi spotlights MS therapies and monitoring
Sanofi’s data at ECTRIMS spotlight advances in tolebrutinib, frexalimab, digital biomarkers, and disease burden studies.
-
RadioMedix and Vect-Horus launch exploratory cancer radiopharmaceutical study
The first patient has been dosed in an exploratory Investigational New Drug (IND) study targeting glioblastoma multiforme and pancreatic cancer.
-
Telix and US FDA set path for glioma imaging agent resubmission
Telix secures FDA resubmission plan for TLX101-CDx after prior setbacks and additional data requests, with NDA filing expected in Q4.
Latest posts
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimizing clinical trial outcomes and guiding effective treatments.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.